GreenLight Clinical and Cure Therapeutics signs Letter of Intent exploring future business collaboration

Home »  GreenLight Clinical and Cure Therapeutics signs Letter of Intent exploring future business collaboration

On 1 March, GreenLight Clinical and Cure Therapeutics held a signing ceremony at GreenLight Clinical’s head office in Sydney, Australia recognizing the execution of a signed Letter of Intent (LOI) between the two companies. Dr. Grace Pei, CEO of GreenLight Clinical, and David Kim, CEO of Cure Therapeutics were both in attendance and signed the document.

The LOI provides GreenLight Clinical and Cure Therapeutics to work together to evaluate a proposed Phase I study for patients with Relapsed/Refractory Multiple Myeloma.

At any given time, about 20,000 people in Australia are living with Myeloma. Every year, more than 2,000 patients are diagnosed with this disease, and more than 1,000 will die from it. There is no cure currently for Myeloma. GreenLight Clinical is excited to be part of the project sponsored by Cure Therapeutics, to develop new treatments for patients with late-stage Myeloma. Both companies hold patient safety as a critical priority and look forward to helping patients with unmet medical needs.

GreenLight CEO Dr. Grace Pei stated “We are excited for the opportunity to partner with Cure Therapeutics in pursuit of a treatment for patients with this potentially fatal condition. This Letter of Intent represents the first step in what we hope will be a long and successful working relationship between our respective companies for our patients”

Mr. David Kim, CEO of Cure Therapeutics, stated “we are very happy to team up with GreenLight to speed up the clinical availability of our unique NK cell therapy for MM patients who do not have any therapeutic options. In addition to collaboration for the first clinical study of our NK cell therapy, we will expand our partnership with GreenLight to accelerate the translation of our innovative therapeutic technologies into curable and affordable solutions for patients with life-threatening conditions.

Both companies expressed their commitment to the bringing innovative treatment to patients with unmet medical needs. The collaboration between the two companies is expected to mutually support the growing healthcare industry in Australia and Korea.

About Cure Therapeutics

Cure Therapeutics is a biotech company with two platform technologies to develop immunotherapy for malignance which does not respond to currently available medications. Cure Therapeutics is actively working on translation of its first Natural Killer Cell technology into a true therapy for Multiple Myeloma through clinical study in Australia while they are also accelerating the development of their unique immunotherapy technology, called Immune Cell Recruiter(ICR) enhancing the migration and infiltration of effector immune cells into tumor microenvironment

About GreenLight Clinical

GreenLight Clinical is a physician-led, boutique full-service clinical CRO with its own central clinical, bioanalytical, and histopathology laboratory in Sydney, Australia. GreenLight Clinical has offices in Australia and USA, with a global footprint. We were founded in 2015 as a CRO by Dr. Andrew Chang, expanding to laboratory services in 2020. Combining medical expertise and deep industry knowledge, GreenLight Clinical develops bespoke solutions to accelerate innovative treatment development for patients with unmet needs.

For more information, please contact:

Dr David Kim
Cure Therapeutics

Michelle Granzow
Marketing Manager
GreenLight Clinical

GLC and CURE team holding ribbon